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Study Objective: This study aimed to evaluate the effects of zolpidem CR (controlled release) on sleep and nocturnal ventilation in patients with congestive 
heart failure, a population at risk for insomnia and poor sleep quality.
Methods: Fifteen patients with heart failure (ischemic cardiomyopathy) and ejection fraction ≤ 45% in NYHA functional class I or II were evaluated with 
full polysomnography in a placebo-controlled, double-blind, randomized trial. Patients underwent three tests: (1) baseline polysomnography and, after 
randomization, (2) a new test with zolpidem CR 12.5 mg or placebo, and after 1 week, (3) a new polysomnography, crossing the “medication” used.
Results: A 16% increase in total sleep time was found with the use of zolpidem CR and an increase in stage 3 NREM sleep (slow wave sleep). The apnea 
hypopnea index (AHI) did not change with zolpidem CR even after controlling for supine position; however, a slight but significant decrease was observed in 
lowest oxygen saturation compared with baseline and placebo conditions (83.60 ± 5.51; 84.43 ± 3.80; 80.71 ± 5.18, P = 0.002).
Conclusion: Zolpidem CR improved sleep structure in patients with heart failure, did not change apnea hypopnea index, but slightly decreased lowest 
oxygen saturation.
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INTRODUCTION
Cardiovascular diseases are the most prevalent chronic dis-
eases in the world1 and result in heart failure (HF) symptoms,2 
associated comorbidities, and poor quality of life.
Sleep disorders are common in HF patients, with approxi-
mately 75% of patients reporting poor sleep. Among these 
disorders, insomnia and sleep apnea4 are the most common.4 
Insomnia occurs in 25% to 56% of patients with HF,5 and sleep 
apnea occurs in 47% to 83% of cases, as they have common 
pathophysiological processes, such as increased sympathetic 
activation and increased sodium and water retention.6 In ad-
dition, insomnia is associated with an increased risk for car-
diovascular disease possibly mediated by hypertension or 
elevated resting heart rate,7 which could negatively affect HF 
patients’ clinical outcomes.
In many of these patients, HF itself, associated with sleep 
disturbances, leads to nocturnal sleep disruption and con-
sequent poor sleep quality, exacerbating heart condition 
symptoms.8 Eventually, this clinical picture, associated with 
complaints of insomnia and/or excessive daytime sleepiness, 
makes these patients seek medical help to try to circumvent 
the problem.9
Among the most commonly prescribed hypnotics are ben-
zodiazepines; however, these drugs may present potential de-
pressant effects on the ventilatory responses of elderly patients 
or in those for whom this response is already compromised; 
these types of medication may also result in addiction.10 In con-
trast to benzodiazepines, zolpidem is a non-benzodiazepine 
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Significance
Sleep disorders are common in patients with heart failure (HF). Caution is recommended when prescribing sedative-hypnotic drugs in this population, 
they may cause depression of ventilation. Given the high prevalence of HF and insomnia; the deleterious nature of this association; the need of 
treatment alternatives to improve sleep; and the low potential of zolpidem to cause respiratory depression, we report data from our randomized, placebo-
controlled, crossover trial, showing that a single dose of zolpidem CR was safe, improved sleep, did not change RDI, but caused a slight but significant 
decrease in lowest SpO2 in a homogeneous sample of HF patients. Despite zolpidem CR having an acute safe profile, its long-term effect in HF patients 
who complain of insomnia deserves further study.
GABA-A receptor agonist that has been widely prescribed 
to treat insomnia.11 A recent review reported the results of 2 
studies in severe obstructive sleep apnea patients using 10 to 
20 mg of zolpidem. Compared with placebo, zolpidem did not 
worsen AHI; however, 20 mg reduced lowest oxygen satura-
tion without changing the oxygen desaturation index.12 Since 
sleep-disordered breathing, either obstructive and central, and 
insomnia are prevalent among HF patients,3–6,8 and no studies 
have evaluated the effect of non-benzodiazepine GABA-A re-
ceptor agonists on breathing during sleep in patients with HF 
of ischemic etiology, we sought to evaluate the effects of zol-
pidem on sleep and nocturnal ventilation in this group. Our 
hypothesis is that zolpidem CR improves polysomnographic 
nocturnal sleep parameters in patients with New York Heart 
Association (NYHA) Class I or II HF.
METHODS
Population
A total of 15 consecutive patients aged over 30 were evaluated. 
They were recruited from the outpatient clinic of the Sao Paulo 
Cardiomyopathy Division, Sao Paulo Hospital, Universidade 
Federal de Sao Paulo, after clinical and laboratory evaluations 
and diagnosis of ischemic cardiomyopathy and ejection frac-
tion ≤ 45% in NYHA functional class I or II. Patients who 
had regularly used benzodiazepines or other medication to in-
duce sleep in the previous month were excluded. In addition, 
we excluded patients with laboratory test changes suggestive 
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of liver and/or kidney failure. Therefore, plasma creatinine 
values ≥ 1.3 mg/dL led to exclusion from the protocol. Fifteen 
patients were included in the final sample. All patients were 
taking medication, including β-blockers, for treatment of their 
heart condition in accordance with the standard outpatient 
treatment protocol.
Sociodemographic data, such as body mass index (BMI), 
age, gender, and neck circumference, and echocardiographic 
data, such as the diameter of the heart cavities, cardiac mass 
index, and ejection fraction, were also evaluated.
Study Design
This study was a double-blind, randomized, placebo-controlled, 
crossover trial. Patients underwent baseline polysomnography 
and were randomized into two groups. A further polysomno-
gram was then performed after taking 12.5 mg zolpidem CR 
or placebo. After a further week, another polysomnogram was 
performed, switching the “medication” used on the second ex-
amination day. There was a washout period of one week be-
tween polysomnograms. Bedtime was stipulated preferably by 
the patient according to their routine and was evaluated using 
a sleep diary.
Polysomnography
Full polysomnography was performed at the Sleep Institute 
laboratory (AFIP, Sao Paulo, Brazil), Sleep Medicine Divi-
sion, Psychobiology Department, (Universidade Federal de 
Sao Paulo, Brazil), at three points: the first evaluation was per-
formed on the first test day (baseline), and the other two evalu-
ations were performed with intervals of one week between 
them (treatment with zolpidem CR or placebo).
The overnight polysomnography was performed using 
an EMBLA digital system (17 channels, Medicare Medical 
Devices). The following variables were monitored: elec-
troencephalogram (4 channels), electrooculogram (2 chan-
nels), electromyogram (2 channels: submental and anterior 
tibialis muscles), electrocardiogram (one channel D2 modi-
fied), snoring, and body position. The airflow was monitored 
using a thermocouple and a nasal pressure transducer (Pro-
Tech Services Inc., Mukilteo, Washington). Chest and ab-
dominal piezo-sensors monitored the respiratory effort of each 
patient. Arterial oxygen saturation (SpO2) and pulse were re-
corded using a pulse oximeter (Nonin, model 9500, Plymouth, 
USA). All of the polysomnograms were performed and scored 
by an experienced sleep technician who followed the Amer-
ican Academy of Sleep Medicine (AASM) guidelines for sleep 
studies13 and were reviewed by a sleep medicine physician.
Sleep Quality Questionnaires
On the first day of baseline polysomnography, patients com-
pleted the following questionnaires: the Epworth Sleepiness 
Scale (ESS)14; the Pittsburgh Sleep Quality Index (PSQI)15; the 
New York Heart Association Functional Classification (NY-
HAFC)16; dyspnea scales17; and the Modified Medical Research 
Council (MMRC) scale.18
Statistical Analysis
The software Statistica v12 (Statsoft, Tulsa, OK, USA) was 
used for data analysis. All demographic, anthropometric, 
echocardiographic, and polysomnographic data are presented 
as means ± standard deviations or frequencies. To compare 
the means of the polysomnographic data, analysis of variance 
(ANOVA) for repeated measures was used followed by the 
Bonferroni a posteriori test when needed. The significance 
level adopted was P ≤ 0.05.
RESULTS
Demographic, Anthropometric, and Echocardiographic 
Evaluations
No adverse event was reported with zolpidem CR or placebo 
in this trial, with the exception of a mild morning headache 
episode in one patient.
The descriptive characteristics of the sample are presented 
in Table 1. Table 1 shows that the population studied presented 
borderline sleepiness score on the Epworth Sleepiness Scale 
(ESS), which was 9.73 ± 5.15 points (excessive sleepiness is 
considered when > 10). However, the population exhibited 
a score of 9.13 ± 5.20 on the Pittsburgh Sleep Quality Index 
(PSQI), suggesting poor sleep quality. Scores on the Medical 
Research Council scale, which measures dyspnea during ex-
ercise, of 1.47 ± 1.30, and on the modified Borg scale of 1.93 
± 2.31, indicate mild to moderate weariness, reinforcing the 
condition presented by our sample of 1.73 ± 0.97 on the NYHA 
functional class scale (data presented in Table 1).
Table 2 shows the echocardiographic parameters of the HF 
patients. As expected, they had low ejection fraction, left ven-
tricular dilation, and reduced cardiac mass index, character-
izing cardiac involvement.
Polysomnography
The patients’ polysomnographic data obtained after the three 
tests are shown in Table 3. Significant differences can be ob-
served in the N3 stage and TST, which increased with the use 
Table 1—Demographic and anthropometric data (n = 15).
Age (years) 59.13 ± 7.60
Weight (kg) 67.89 ± 13.32
Height (m) 1.63 ± 0.10
BMI (kg/m2) 25.54 ± 3.74
Night neck circumference (cm) 38.23 ± 3.69
Morning neck circumference (cm) 37.54 ± 3.83
Abdominal circumference (cm) 95.93 ± 10.76
Hip circumference (cm) 94.33 ± 9.09
Waist/hip ratio 1.02 ± 0.06
ESS (score) 9.73 ± 5.15
PSQI (score) 9.13 ± 5.20
NYHA (class) 1.73 ± 0.97
British Council scale (score) 1.47 ± 1.30
Modified Borg scale (score) 1.93 ± 2.31
Values presented as mean ± standard deviation. ESS, Epworth 
sleepiness scale; PSQI, Pittsburg sleep quality index; NYHA, functional 
class according to the New York Heart Association.
{P = 0.068
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of zolpidem CR (P = 0.01 for both). The other sleep architec-
ture parameters did not differ between treatments. In relation 
to respiratory sleep parameters, no significant change was 
detected in the apnea-hypopnea index (AHI), the respiratory 
disturbance index (RDI), or the central or obstructive respira-
tory event index during REM sleep, NREM sleep, or sleep in 
the supine position between treatments. Minimum O2 satura-
tion was lower in the zolpidem CR group (P = 0.002); however, 
the percentage of time with oxygen saturation less than 90% 
and the mean saturation did not differ significantly between 
treatments.
DISCUSSION
This is the first study, to the best of our knowledge, assessing 
the acute effect of a non-benzodiazepine GABA-A receptor 
agonist, in this case zolpidem CR, in HF patients with reduced 
ejection fraction. Overall results suggest that zolpidem in-
creased total sleep time and N3 NREM sleep compared with 
placebo and baseline. We did not find significant changes in 
AHI and RDI, even after controlling for supine position. How-
ever, a slight but significant decrease in lowest SpO2 was found 
with zolpidem compared with placebo and baseline conditions.
There have been a number of reports in the literature on 
HF patients suggesting that they have poor sleep quality as as-
sessed by PSQI,19,20 and fragmented sleep for various reasons, 
Table 3—Comparison of polysomnographic data: baseline, placebo and zolpidem CR conditions (n = 15).
Variable Baseline Mean Placebo Zolpidem CR P value
Sleep latency (min) 29.05 ± 30.04 25.31 ± 44.97 17.19 ± 20.75 0.677
REM latency (min) 132.47 ± 82.45 116.18 ± 81.62 139.93 ± 88.62 0.540
TST (min) 324.70 ± 84.11 330.25 ± 78.04 383.29 ± 68.89* 0.017
SE (%) 71.91 ± 17.79 74.85 ± 17.93 82.84 ± 13.11 0.068
N1 (%) 17.08 ± 10.22 15.86 ± 12.24 13.71 ± 13.55 0.336
N2 (%) 46.41 ± 11.48 42.41 ± 10.83 44.02 ± 10.05 0.333
N3 (%) 20.44 ± 8.82 22.44 ± 10.93 27.11 ± 13.64* 0.015
REM (%) 16.11 ± 4.96 19.54 ± 7.26 15.16 ± 8.68 0.066
WASO (min) 97.37 ± 54.69 90.69 ± 77.41 62.36 ± 48.12 0.137
Arousals (events/h) 20.83 ± 7.46 19.89 ± 10.27 17.65 ± 12.28 0.453
Respiratory events (n) 139.27 ± 88.94 128.57 ± 81.57 145.14 ± 92.76 0.719
Obstructive apnea (events/h) 3.00 ± 4.34 3.71 ± 3.02 5.76 ± 4.92 0.174
Obstructive apnea REM (events/h) 2.66 ± 3.82 5.69 ± 7.78 9.96 ± 14.19 0.100
Obstructive apnea supine (events/h) 5.28 ± 9.78 8.41 ± 8.42 12.25 ± 13.90 0.377
Central apnea (events/h) 7.21 ± 13.14 9.89 ± 17.58 5.45 ± 13.97 0.626
Central apnea REM (events/h) 1.05 ± 1.59 4.26 ± 14.66 3.11 ± 11.46 0.669
Central apnea supine (events/h) 11.95 ± 19.15 12.85 ± 19.53 10.65 ± 16.29 0.739
RDI (events/h) 25.23 ± 15.52 24.44 ± 15.68 23.89 ± 17.62 0.817
AHI (events/h) 22.41 ± 16.44 22.81 ± 16.31 22.16 ± 17.72 0.938
AHI in REM (events/h) 17.58 ± 9.20 25.45 ± 19.38 24.91 ± 24.12 0.376
AHI supine (events/h) 42.22 ± 29.78 36.74 ± 19.74 39.94 ± 29.02 0.812
Apnea (events/h) 11.69 ± 14.66 14.42 ± 17.91 12.56 ± 15.26 0.830
Hypopnea (events/h) 10.71 ± 8.37 8.41 ± 4.77 9.60 ± 6.10 0.334
Time spent in supine position (%) 47.46 ± 32.75 50.79 ± 33.30 47.88 ± 33.13 0.878
SpO2 baseline (%) 94.27 ± 1.71 94.29 ± 2.09 93.73 ± 2.33 0.336
SpO2 mean (%) 93.41 ± 1.74 93.19 ± 2.29 92.45 ± 2.56 0.082
Lowest SpO2 (%) 83.60 ± 5.51 84.43 ± 3.80 80.71 ± 5.18* 0.002
REM desaturation (events/h) 21.55 ± 16.02 22.48 ± 16.44 26.26 ± 27.42 0.747
NREM desaturation (events/h) 22.85 ± 20.60 20.66 ± 17.20 21.39 ± 17.13 0.718
SpO2 < 90 (%) 7.33 ± 9.54 13.29 ± 22.43 18.86 ± 26.66 0.104
Values presented as mean ± standard deviation. ANOVA for repeated measures. *P ≤ 0.05 zolpidem CR differs from baseline and placebo. TST, total sleep 
time; SE, sleep efficiency; WASO, wake after sleep onset; AHI, apnea hypopnea index; RDI, respiratory disturbance index.
Table 2—Echocardiographic data (n = 15).
Aortic diameter (mm) 32 ± 3
LV diameter (mm) 40 ± 4
LV diastolic diameter (mm) 58 ± 6
IV septum thickness (mm) 9 ± 1
Mass index (g/m2) 135 ± 31
LV ejection fraction (%) 32 ± 7
Values presented as mean ± standard deviation. LV, left ventricle; IV, 
interventricular.
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such as sleep apnea and insomnia.4,5 Similarly, we found poor 
sleep quality using similar questionnaire, a mean baseline AHI 
of 22.41 ± 16.44, and fragmented sleep as evidenced by in-
creased WASO and arousal index in our population.
There is no consensus on the best sleep-inducing medica-
tion for patients with HF. As zolpidem is one of the most com-
monly prescribed hypnotics,21 and reported to be safe with few 
dose-dependent adverse events,22 in this study we decided to 
evaluate its effects in a homogeneous sample of patients with 
HF of ischemic origin, which, with hypertension, is the most 
common etiology of HF.23 Patients did not report significant 
adverse events after a single dose of zolpidem CR, with the 
exception of a mild morning headache episode in one patient.
Unlike benzodiazepines, in healthy controls, zolpidem has 
little effect on sleep stages.24 Zolpidem is as effective as ben-
zodiazepines in decreasing sleep latency and prolonging TST 
in patients with insomnia.25,26 In fact, our study showed that in 
patients with ischemic HF, zolpidem CR prolongs TST by an 
average of 16% compared to placebo. We also observed a trend 
toward an increase in sleep efficiency compared with placebo 
(P = 0.06). As for sleep stages, there was a significant increase 
in N3 in the zolpidem CR group. The combination of increased 
TST and increased N3 stage (slow wave sleep) indicates an 
improvement in the sleep pattern, which in theory could be 
beneficial for patients with HF, since N3 is a sleep stage where 
cardiac demand is at its lowest for the day, as a lower heart 
rate, blood pressure, and respiratory rate are observed.27 REM 
sleep, however, did not change significantly with the use of 
zolpidem CR. Together, these results suggest an improvement 
in sleep architecture in patients with HF acutely treated with 
zolpidem CR.
With regard to potential breathing effects, zolpidem has 
been reported as having fewer muscle-relaxant effects than 
benzodiazepine hypnotics, which has been mostly studied 
in animals.28 In our study, zolpidem CR showed a slight but 
statistically significant reduction in lowest oxygen saturation. 
A previous study also showed similar results in severe OSA 
patients without HF; a slight reduction in lowest oxygen satu-
ration with no changes in AHI with a higher than usual thera-
peutic dose, 20 mg of zolpidem.29 Moreover, studies show that 
another GABA-A agonist, eszopiclone, may not change30 or 
may even improve breathing patterns during sleep, especially 
for individuals whose sleep is highly fragmented, and thus for 
whom the ventilatory drive becomes unstable.31
However, some guidelines suggest that this drug should not 
be used in patients with respiratory depression.32 This effect 
could be attributed to an effect within the central chemore-
flex loop at the central chemoreceptors,33 which could actu-
ally reduce respiratory events in patients with HF and central 
sleep apnea. Zolpidem has been reported as devoid of muscle-
relaxant effects, thus unlikely to affect oropharyngeal mus-
cles24; and does not cause respiratory depression in insomnia 
patients.26 Similarly, our study revealed that in patients with 
ischemic HF, no significant increase in obstructive respiratory 
events, in overall AHI or RDI, or in OSA and CSA indices per 
hour were detected compared with placebo and baseline con-
ditions. The only study, to the best of our knowledge, evalu-
ating the long-term effects of zolpidem on sleep parameters in 
patients with OSA treated with CPAP, reported an improve-
ment in sleep latency and arousal index, without affecting AHI, 
ODI, and lowest SpO2, compared with placebo.34
Another issue to be considered when computing the number 
of obstructive or central apneas is the time spent in the supine 
position, which is known to possibly increase obstructive and 
even central events.35 In our study, we also evaluated the respi-
ratory disturbance indices during sleep in the supine position 
and found no differences.
Potential limitations of this study include the relatively 
small sample size, although other studies evaluating popula-
tions with sleep-disordered breathing and the use of sleep aids 
used similar or smaller samples including sample sizes calcu-
lation to detect a significant difference in AHI of 5 per hour.34 
In addition, we did not evaluate the duration of respiratory 
events but did control for supine position and type of events. 
Lastly, our data refer only to a single dose. Despite zolpidem 
CR having an acute safe profile, its long-term effect in HF pa-
tients who complain of insomnia deserves further study.
CONCLUSIONS
The hypnotic zolpidem CR improves sleep structure because 
it increases N3, a deep sleep phase, and TST. Zolpidem CR 
also tends to increase sleep efficiency, which can be beneficial 
for the cardiovascular system. Furthermore, zolpidem CR did 
not increase the overall rate of apneas and hypopneas and de-
creased lowest oxygen saturation without affecting respiratory 
events of central origin.
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